Syk-induced phosphatidylinositol-3-kinase activation in epstein-barr virus posttransplant lymphoproliferative disorder

American Journal of Transplantation

Volumn 13, Issue 4, 2013, Pages 883-890

  Hatton, O ^a   Lambert, S L ^a,b   Phillips, L K ^a   Vaysberg, M ^a,c   Natkunam, Y ^a   Esquivel, C O ^a   Krams, S M ^a   Martinez, O M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

^c Gilead   (United States)

Author keywords

Epstein Barr virus; PI 3 kinase Akt pathway; posttransplant lymphoproliferative disorder; PTLD

Indexed keywords

FOSTAMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE SYK;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INGUINAL LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL CYCLE; CELL LINE, TUMOR; ENZYME ACTIVATION; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPH NODES; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; OXAZINES; PHOSPHATIDYLINOSITOL 3-KINASES; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875719027     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12137     Document Type: Article

References (24)

1. Young LS, Rickinson AB,. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768. (Pubitemid 39331148)
2. Snow AL, Martinez OM,. Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 2007; 7: 271-277. (Pubitemid 46096319)
3. Beatty PR, Krams SM, Martinez OM,. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 1997; 158: 4045-4051. (Pubitemid 127483901)
4. Gottschalk S, Rooney CM, Heslop HE,. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44. (Pubitemid 40299772)
5. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R,. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998; 9: 405-411. (Pubitemid 28462761)
6. Snow AL, Chen LJ, Nepomuceno RR, Krams SM, Esquivel CO, Martinez OM,. Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol 2001; 167: 5404-5411. (Pubitemid 33009781)
7. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM,. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B cell lymphomas. Cancer Res 2003; 63: 4472-4480. (Pubitemid 36951019)
8. Lambert SL, Martinez OM,. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 2007; 179: 8225-8234.
9. Irish JM, Czerwinski DK, Nolan GP, Levy R,. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006; 177: 1581-1589. (Pubitemid 44092493)
10. Fu C, Turck CW, Kurosaki T, Chan AC,. BLNK: A central linker protein in B cell activation. Immunity 1998; 9: 93-103. (Pubitemid 28361298)
11. Wienands J, Schweikert J, Wollscheid B, Jumaa H, Nielsen PJ, Reth M,. SLP-65: A new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation. J Exp Med 1998; 188: 791-795. (Pubitemid 28387943)
12. Hatton O, Phillips LK, Vaysberg M, Hurwich J, Krams SM, Martinez OM,. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas. J Biol Chem 2011; 286: 37368-37378.
13. Yuan TL, Cantley LC,. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510.
14. Courtney KD, Corcoran RB, Engelman JA,. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083.
15. Weinstein IB, Joe A,. Oncogene addiction. Cancer Res 2008; 68: 3077-3080; discussion 3080.
16. Gururajan M, Dasu T, Shahidain S, et al. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol 2006th ed. 2007; 178: 111-121. (Pubitemid 46033592)
17. Young RM, Hardy IR, Clarke RL, et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009; 113: 2508-2516.
18. Suljagic M, Longo PG, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B cell receptor signaling. Blood 2010; 116: 4894-4905.
19. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.
20. Gobessi S, Laurenti L, Longo PG, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009; 23: 686-697.
21. Buchner M, Fuchs S, Prinz G, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009; 69: 5424-5432.
22. Mõcsai A, Ruland J, Tybulewicz VLJ,. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol 2010; 10: 387-402.
23. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006; 319: 998-1008.
24. Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115: 4497-4506.